Dr. Jay Siegel is Chief Biotechnology Officer and Head of Scientific Strategy and Policy, Johnson & Johnson. In these roles, he is actively engaged in research and development (R&D) leadership, and in policy development at the national and international levels with regard to scientific and regulatory issues.
Dr. Siegel joined Johnson & Johnson in 2003 as President of Centocor Research & Development, Inc., and subsequently served as Group President of R&D with oversight of research and development in Biotechnology, Immunology and Oncology. Dr. Siegel later served as Head of Global Regulatory Affairs for Janssen, the pharmaceutical companies of Johnson & Johnson, and also led Janssen’s Biotechnology Center of Excellence.
Before joining Johnson & Johnson, Dr. Siegel spent 20 years at the United States Food and Drug Administration (FDA) Center for Biologics Evaluation & Research in positions of increasing responsibility regulating the biotechnology industry.
Dr. Siegel received a Bachelor of Science in Biology from the California Institute of Technology and an medical degree from Stanford University. He trained in Internal Medicine at the University of California, San Francisco, and in Infectious Diseases and Immunology at Stanford University.
Dr. Siegel is recipient of numerous honors including the United States Public Health Service’s highest honor, the Distinguished Service Medal and, twice, the U.S. Health & Human Services Secretary’s Award for Distinguished Service. He has been elected to fellowship in the American College of Physicians and the Society for Clinical Trials and has authored numerous publications in the areas of clinical trial design, biotechnology, immunology, and drug development policy. He currently serves on the Executive Committees and the Boards of Directors of the Biotechnology Industry Organization (BIO) and the Alliance for Regenerative Medicine.